Does RISANKIZUMAB-RZAA Cause Neoplasm malignant? 715 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 715 reports of Neoplasm malignant have been filed in association with RISANKIZUMAB-RZAA. This represents 1.1% of all adverse event reports for RISANKIZUMAB-RZAA.
715
Reports of Neoplasm malignant with RISANKIZUMAB-RZAA
1.1%
of all RISANKIZUMAB-RZAA reports
24
Deaths
61
Hospitalizations
How Dangerous Is Neoplasm malignant From RISANKIZUMAB-RZAA?
Of the 715 reports, 24 (3.4%) resulted in death, 61 (8.5%) required hospitalization, and 3 (0.4%) were considered life-threatening.
Is Neoplasm malignant Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RISANKIZUMAB-RZAA. However, 715 reports have been filed with the FAERS database.
What Other Side Effects Does RISANKIZUMAB-RZAA Cause?
Psoriasis (6,896)
Drug ineffective (2,885)
Pain (2,584)
Fatigue (2,483)
Arthralgia (2,419)
Pruritus (2,311)
Covid-19 (2,145)
Death (1,700)
Fall (1,666)
Surgery (1,662)
What Other Drugs Cause Neoplasm malignant?
RANITIDINE (10,648)
ADALIMUMAB (2,028)
APIXABAN (1,772)
ETANERCEPT (1,616)
METHOTREXATE (1,041)
TOFACITINIB (1,020)
RITUXIMAB (929)
INFLIXIMAB (892)
ABATACEPT (727)
DENOSUMAB (698)
Which RISANKIZUMAB-RZAA Alternatives Have Lower Neoplasm malignant Risk?
RISANKIZUMAB-RZAA vs RISDIPLAM
RISANKIZUMAB-RZAA vs RISEDRONATE
RISANKIZUMAB-RZAA vs RISEDRONIC ACID
RISANKIZUMAB-RZAA vs RISPERDAL
RISANKIZUMAB-RZAA vs RISPERDAL CONSTA